超声造影对甲状腺癌包膜侵犯、淋巴结转移诊断价值及其与血清 HMGB-1、sIL-2R 相关性研究.

Objective: To explore the diagnostic value of contrast-enhanced ultrasound in thyroid cancer capsule invasion and lymph node metastasis and its correlation with serum high mobility group protein 1(HMGB-1) and soluble interleukin-2 receptor(s IL-2 R). Methods: 156 patients with thyroid nodules admitted to our hospital from February 2019 to August 2020 were selected as the research objects. All patients were confirmed pathologically. According to the pathological results, the envelopment invasion can be divided into the invasion group (86 cases, 55.13%) and the non-invasive group(70 cases, 44.87%). In addition, according to the pathological results, the lymph node metastasis is also divided into The transfer group(92 cases, 58.97%) and the non-transfer group (64 cases,41.03%). Routine ultrasound, contrast-enhanced ultrasound, and serum HMGB-1 and s IL-2 R levels were tested before surgery. Compare the diagnostic efficacy of conventional ultrasound and contrast-enhanced ultrasound in the diagnosis of thyroid capsule invasion and lymph node metastasis, and analyze the correlation with serum HMGB-1 and s IL-2 R levels. Results: Conventional ultrasound and contrast-enhanced ultrasound had statistically significant differences in the diagnosis of thyroid cancer capsule invasion and lymph node metastasis (P<0.05). The accuracy and sensitivity of contrast-enhanced ultrasound in diagnosing thyroid cancer capsule invasion were significantly higher than that of conventional ultrasound (P<0.05), while the differences in specificity, positive predictive value and negative predictive value between the two inspection methods were not statistically significant (P>0.05). The accuracy, sensitivity, specificity, positive predictive value and negative predictive value of contrast-enhanced ultrasound in diagnosing lymph node metastasis of thyroid cancer were significantly higher than those of conventional ultrasound (P<0.05). Serum HMGB-1 and s IL-2 R levels in the thyroid cancer capsule invasion group and lymph node metastasis group were significantly higher than those in the non-invasive group and non-metastasis group (P<0.05). Conclusion: Contrast-enhanced ultrasound has a certain diagnostic value for thyroid cancer capsule invasion and lymph node metastasis, and it is correlated with serum HMGB1 and s IL-2 R levels. Therefore, preoperative contrast-enhanced ultrasound examination and detection of serum HMGB1 and s IL-2 R levels have a certain prompting effect on capsule invasion and lymph node metastasis in patients with thyroid cancer, and can be of great value in the selection of clinical treatment options. [ABSTRACT FROM AUTHOR]